Wellington Management Group LLP Revance Therapeutics, Inc. Transaction History

Wellington Management Group LLP

$557 Billion
Q3 2024

A detailed history of Wellington Management Group LLP transactions in Revance Therapeutics, Inc. stock. As of the latest transaction made, Wellington Management Group LLP holds 446,027 shares of RVNC stock, worth $1.15 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

446,027

Holding current value

$1.15 Million

% of portfolio

0.0%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$2.57 - $2.57 $1.15 Million - $1.15 Million	446,027 New	446,027 $1.15 Million
Q1 2024 May 15, 2024	BUY	$4.65 - $9.31 $355,320 - $711,405	76,413 New	76,413 $375,000
Q4 2023 Feb 12, 2024	BUY	$5.81 - $11.2 $2.61 Million - $5.04 Million	449,685 New	449,685 $3.95 Million
Q3 2023 Nov 14, 2023	BUY	$11.47 - $25.07 $425,892 - $930,874	37,131 Added 3.55%	1,082,420 $12.4 Million
Q2 2023 Aug 14, 2023	SELL	$24.7 - $37.61 $2.37 Million - $3.61 Million	-95,871 Reduced 8.4%	1,045,289 $26.5 Million
Q1 2023 May 12, 2023	SELL	$18.36 - $35.27 $2.82 Million - $5.41 Million	-153,515 Reduced 11.86%	1,141,160 $36.8 Million
Q4 2022 Feb 13, 2023	BUY	$18.32 - $30.66 $17.6 Million - $29.5 Million	961,998 Added 289.17%	1,294,675 $23.9 Million
Q3 2022 Nov 14, 2022	SELL	$14.33 - $28.47 $168,950 - $335,661	-11,790 Reduced 3.42%	332,677 $8.98 Million
Q2 2022 Aug 15, 2022	SELL	$11.52 - $20.4 $3,697 - $6,548	-321 Reduced 0.09%	344,467 $4.76 Million
Q1 2022 May 16, 2022	SELL	$12.36 - $20.31 $8.58 Million - $14.1 Million	-694,124 Reduced 66.81%	344,788 $6.72 Million
Q4 2021 Feb 11, 2022	SELL	$12.46 - $27.87 $2.22 Million - $4.97 Million	-178,181 Reduced 14.64%	1,038,912 $17 Million
Q3 2021 Nov 15, 2021	SELL	$25.78 - $33.21 $40 Million - $51.6 Million	-1,553,147 Reduced 56.07%	1,217,093 $33.9 Million
Q2 2021 Aug 16, 2021	SELL	$26.8 - $31.84 $1.75 Million - $2.08 Million	-65,451 Reduced 2.31%	2,770,240 $82.1 Million
Q1 2021 May 17, 2021	SELL	$24.03 - $29.97 $10.4 Million - $13 Million	-432,426 Reduced 13.23%	2,835,691 $79.3 Million
Q4 2020 Feb 12, 2021	SELL	$23.41 - $28.34 $6.89 Million - $8.35 Million	-294,474 Reduced 8.27%	3,268,117 $92.6 Million
Q3 2020 Nov 16, 2020	SELL	$23.23 - $34.3 $4.51 Million - $6.66 Million	-194,207 Reduced 5.17%	3,562,591 $89.6 Million
Q2 2020 Aug 14, 2020	SELL	$12.6 - $26.55 $23.6 Million - $49.6 Million	-1,869,621 Reduced 33.23%	3,756,798 $91.7 Million
Q1 2020 May 14, 2020	SELL	$12.46 - $27.81 $2.01 Million - $4.49 Million	-161,626 Reduced 2.79%	5,626,419 $83.3 Million
Q4 2019 Feb 11, 2020	BUY	$11.66 - $20.15 $67.5 Million - $117 Million	5,788,045 New	5,788,045 $93.9 Million

Others Institutions Holding RVNC

# of Institutions

234

Shares Held

82.8M

Call Options Held

680K

Put Options Held

896K

View Full List

About Revance Therapeutics, Inc.

Ticker RVNC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,305,696
Market Cap $212M
Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...

More about RVNC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wellington Management Group LLP, based on Form 13F filings with the SEC.

News

Stay updated on Wellington Management Group LLP with notifications on news.

Account

Wellington Management Group LLP Revance Therapeutics, Inc. Transaction History